1 | Non-phosphorylatable cyclin D1 mutant potentiates endometrial hyperplasia and drives carcinoma with Pten loss. (Yoshida A, Phillips-Mason P, Tarallo V, Avril S, Koivisto C, Leone G, Diehl JA) Oncogene 2022 Apr;41(15):2187-2195 4 Citations |
1 | Tetraspanin CD82 is necessary for muscle stem cell activation and supports dystrophic muscle function. (Hall A, Fontelonga T, Wright A, Bugda Gwilt K, Widrick J, Pasut A, Villa F, Miranti CK, Gibbs D, Jiang E, Meng H, Lawlor MW, Gussoni E) Skelet Muscle 2020 Nov 27;10(1):34 9 Citations |
1 | Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma. (Koivisto CS, Parrish M, Bonala SB, Ngoi S, Torres A, Gallagher J, Sanchez-Hodge R, Zeinner V, Nahhas GJ, Liu B, Cohn DE, Backes FJ, Goodfellow PJ, Chamberlin HM, Leone G) Neoplasia 2020 Oct;22(10):484-496 6 Citations |
2 | Divergent mutational processes distinguish hypoxic and normoxic tumours. (Bhandari V, Li CH, Bristow RG, Boutros PC, PCAWG Consortium) Nat Commun 2020 Feb 05;11(1):737 79 Citations |
1 | PTEN in the Stroma. (Thies KA, Lefler JE, Leone G, Ostrowski MC) Cold Spring Harb Perspect Med 2019 Oct 01;9(10) 8 Citations |
1 | Loss of PTEN Accelerates NKX3.1 Degradation to Promote Prostate Cancer Progression. (Bowen C, Ostrowski MC, Leone G, Gelmann EP) Cancer Res 2019 Aug 15;79(16):4124-4134 23 Citations |
1 | Preventive Effects by Black Raspberries of Endometrial Carcinoma Initiation and Promotion Induced by a High-Fat Diet. (Huang YW, Chen JH, Rader JS, Aguilera-Barrantes I, Wang LS) Mol Nutr Food Res 2019 Jun;63(12):e1900013 2 Citations |
1 | FDPS cooperates with PTEN loss to promote prostate cancer progression through modulation of small GTPases/AKT axis. (Seshacharyulu P, Rachagani S, Muniyan S, Siddiqui JA, Cruz E, Sharma S, Krishnan R, Killips BJ, Sheinin Y, Lele SM, Smith LM, Talmon GA, Ponnusamy MP, Datta K, Batra SK) Oncogene 2019 Jun;38(26):5265-5280 37 Citations |
1 | Cell-of-origin susceptibility to glioblastoma formation declines with neural lineage restriction. (Alcantara Llaguno S, Sun D, Pedraza AM, Vera E, Wang Z, Burns DK, Parada LF) Nat Neurosci 2019 Apr;22(4):545-555 88 Citations |
1 | Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. (Millis SZ, Jardim DL, Albacker L, Ross JS, Miller VA, Ali SM, Kurzrock R) Cancer 2019 Apr 01;125(7):1185-1199 36 Citations |
2 | Crosstalk between PKCα and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium. (Hsu AH, Lum MA, Shim KS, Frederick PJ, Morrison CD, Chen B, Lele SM, Sheinin YM, Daikoku T, Dey SK, Leone G, Black AR, Black JD) Cell Rep 2018 Jul 17;24(3):655-669 32 Citations |
2 | Stromal PTEN determines mammary epithelial response to radiotherapy. (Sizemore GM, Balakrishnan S, Thies KA, Hammer AM, Sizemore ST, Trimboli AJ, Cuitiño MC, Steck SA, Tozbikian G, Kladney RD, Shinde N, Das M, Park D, Majumder S, Krishnan S, Yu L, Fernandez SA, Chakravarti A, Shields PG, White JR, Yee LD, Rosol TJ, Ludwig T, Park M, Leone G, Ostrowski MC) Nat Commun 2018 Jul 17;9(1):2783 18 Citations |
1 | Discrete roles and bifurcation of PTEN signaling and mTORC1-mediated anabolic metabolism underlie IL-7-driven B lymphopoiesis. (Zeng H, Yu M, Tan H, Li Y, Su W, Shi H, Dhungana Y, Guy C, Neale G, Cloer C, Peng J, Wang D, Chi H) Sci Adv 2018 Jan;4(1):eaar5701 30 Citations |
2 | PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform. (Ronen S, Abbott DW, Kravtsov O, Abdelkader A, Xu Y, Banerjee A, Iczkowski KA) Hum Pathol 2017 Jul;65:85-91 32 Citations |
4 | Integrated genomic and molecular characterization of cervical cancer. (Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, Barretos Cancer Hospital, Baylor College of Medicine, Beckman Research Institute of City of Hope, Buck Institute for Research on Aging, Canada's Michael Smith Genome Sciences Centre, Harvard Medical School, Helen F. Graham Cancer Center &Research Institute at Christiana Care Health Services, HudsonAlpha Institute for Biotechnology, ILSbio, LLC, Indiana University School of Medicine, Institute of Human Virology, Institute for Systems Biology, International Genomics Consortium, Leidos Biomedical, Massachusetts General Hospital, McDonnell Genome Institute at Washington University, Medical College of Wisconsin, Medical University of South Carolina, Memorial Sloan Kettering Cancer Center, Montefiore Medical Center, NantOmics, National Cancer Institute, National Hospital, Abuja, Nigeria, National Human Genome Research Institute, National Institute of Environmental Health Sciences, National Institute on Deafness &Other Communication Disorders, Ontario Tumour Bank, London Health Sciences Centre, Ontario Tumour Bank, Ontario Institute for Cancer Research, Ontario Tumour Bank, The Ottawa Hospital, Oregon Health &Science University, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, SRA International, St Joseph's Candler Health System, Eli &Edythe L. Broad Institute of Massachusetts Institute of Technology &Harvard University, Research Institute at Nationwide Children's Hospital, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, University of Bergen, University of Texas MD Anderson Cancer Center, University of Abuja Teaching Hospital, University of Alabama at Birmingham, University of California, Irvine, University of California Santa Cruz, University of Kansas Medical Center, University of Lausanne, University of New Mexico Health Sciences Center, University of North Carolina at Chapel Hill, University of Oklahoma Health Sciences Center, University of Pittsburgh, University of São Paulo, Ribeir ão Preto Medical School, University of Southern California, University of Washington, University of Wisconsin School of Medicine &Public Health, Van Andel Research Institute, Washington University in St Louis) Nature 2017 Mar 16;543(7645):378-384 974 Citations |
1 | The application of CRISPR technology to high content screening in primary neurons. (Callif BL, Maunze B, Krueger NL, Simpson MT, Blackmore MG) Mol Cell Neurosci 2017 Apr;80:170-179 11 Citations |
1 | Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer. (Hosford SR, Dillon LM, Bouley SJ, Rosati R, Yang W, Chen VS, Demidenko E, Morra RP Jr, Miller TW) Clin Cancer Res 2017 Jun 01;23(11):2795-2805 26 Citations |
2 | Stromal PTEN inhibits the expansion of mammary epithelial stem cells through Jagged-1. (Sizemore GM, Balakrishnan S, Hammer AM, Thies KA, Trimboli AJ, Wallace JA, Sizemore ST, Kladney RD, Woelke SA, Yu L, Fernandez SA, Chakravarti A, Leone G, Ostrowski MC) Oncogene 2017 Apr 20;36(16):2297-2308 20 Citations |
1 | Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors. (Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R) JAMA Oncol 2016 Dec 01;2(12):1565-1573 186 Citations |
1 | PTEN recruitment controls synaptic and cognitive function in Alzheimer's models. (Knafo S, Sánchez-Puelles C, Palomer E, Delgado I, Draffin JE, Mingo J, Wahle T, Kaleka K, Mou L, Pereda-Perez I, Klosi E, Faber EB, Chapman HM, Lozano-Montes L, Ortega-Molina A, Ordóñez-Gutiérrez L, Wandosell F, Viña J, Dotti CG, Hall RA, Pulido R, Gerges NZ, Chan AM, Spaller MR, Serrano M, Venero C, Esteban JA) Nat Neurosci 2016 Mar;19(3):443-53 109 Citations |
1 | FGFR and PTEN signaling interact during lens development to regulate cell survival. (Chaffee BR, Hoang TV, Leonard MR, Bruney DG, Wagner BD, Dowd JR, Leone G, Ostrowski MC, Robinson ML) Dev Biol 2016 Feb 15;410(2):150-163 20 Citations |
1 | Endothelial Cell Surface Expressed Chemotaxis and Apoptosis Regulator (ECSCR) Regulates Lipolysis in White Adipocytes via the PTEN/AKT Signaling Pathway. (Kilari S, Cossette S, Pooya S, Bordas M, Huang YW, Ramchandran R, Wilkinson GA) PLoS One 2015;10(12):e0144185 8 Citations |
1 | Adult Lineage-Restricted CNS Progenitors Specify Distinct Glioblastoma Subtypes. (Alcantara Llaguno SR, Wang Z, Sun D, Chen J, Xu J, Kim E, Hatanpaa KJ, Raisanen JM, Burns DK, Johnson JE, Parada LF) Cancer Cell 2015 Oct 12;28(4):429-440 146 Citations |
1 | Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. (Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S) J Clin Oncol 2015 Dec 01;33(34):4023-31 410 Citations |
1 | Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo. (Caserta E, Egriboz O, Wang H, Martin C, Koivisto C, Pecót T, Kladney RD, Shen C, Shim KS, Pham T, Karikomi MK, Mauntel MJ, Majumder S, Cuitino MC, Tang X, Srivastava A, Yu L, Wallace J, Mo X, Park M, Fernandez SA, Pilarski R, La Perle KM, Rosol TJ, Coppola V, Castrillon DH, Timmers C, Cohn DE, O'Malley DM, Backes F, Suarez AA, Goodfellow P, Chamberlin HM, Macrae ER, Shapiro CL, Ostrowski MC, Leone G) Genes Dev 2015 Aug 15;29(16):1707-20 26 Citations |
1 | Viral vector-based improvement of optic nerve regeneration: characterization of individual axons' growth patterns and synaptogenesis in a visual target. (Yungher BJ, Luo X, Salgueiro Y, Blackmore MG, Park KK) Gene Ther 2015 Oct;22(10):811-21 51 Citations |
1 | Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer. (Schwaederle M, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R) Cell Cycle 2015;14(11):1730-7 9 Citations |
1 | Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. (Xia S, Kohli M, Du M, Dittmar RL, Lee A, Nandy D, Yuan T, Guo Y, Wang Y, Tschannen MR, Worthey E, Jacob H, See W, Kilari D, Wang X, Hovey RL, Huang CC, Wang L) Oncotarget 2015 Jun 30;6(18):16411-21 39 Citations |
1 | Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. (Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J) Invest New Drugs 2015 Jun;33(3):700-9 13 Citations |
1 | Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. (Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R) Ann Oncol 2015 Jul;26(7):1346-52 48 Citations |
1 | Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. (Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R) Cell Cycle 2015;14(8):1252-9 40 Citations |
1 | PTEN is a negative regulator of NK cell cytolytic function. (Briercheck EL, Trotta R, Chen L, Hartlage AS, Cole JP, Cole TD, Mao C, Banerjee PP, Hsu HT, Mace EM, Ciarlariello D, Mundy-Bosse BL, Garcia-Cao I, Scoville SD, Yu L, Pilarski R, Carson WE 3rd, Leone G, Pandolfi PP, Yu J, Orange JS, Caligiuri MA) J Immunol 2015 Feb 15;194(4):1832-40 34 Citations |
1 | Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. (Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S) Oncotarget 2014 Nov 30;5(22):11168-79 53 Citations |
1 | Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. (Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R) Invest New Drugs 2015 Feb;33(1):215-24 9 Citations |
1 | Actin dynamics is rapidly regulated by the PTEN and PIP2 signaling pathways leading to myocyte hypertrophy. (Li J, Tanhehco EJ, Russell B) Am J Physiol Heart Circ Physiol 2014 Dec 01;307(11):H1618-25 27 Citations |
1 | Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. (Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R) Breast Cancer Res 2014 Sep 11;16(5):430 63 Citations |
1 | Stat5 regulates the phosphatidylinositol 3-kinase/Akt1 pathway during mammary gland development and tumorigenesis. (Schmidt JW, Wehde BL, Sakamoto K, Triplett AA, Anderson SM, Tsichlis PN, Leone G, Wagner KU) Mol Cell Biol 2014 Apr;34(7):1363-77 55 Citations |
1 | Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. (Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R) Cell Rep 2014 Jan 30;6(2):377-87 200 Citations |
1 | Therapeutic targeting of cancers with loss of PTEN function. (Dillon LM, Miller TW) Curr Drug Targets 2014 Jan;15(1):65-79 183 Citations |
1 | Targeting SRC and tubulin in mucinous ovarian carcinoma. (Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer DG, Coleman RL, Frumovitz M, Sood AK) Clin Cancer Res 2013 Dec 01;19(23):6532-43 33 Citations |
1 | Redox signaling via oxidative inactivation of PTEN modulates pressure-dependent myogenic tone in rat middle cerebral arteries. (Gebremedhin D, Terashvili M, Wickramasekera N, Zhang DX, Rau N, Miura H, Harder DR) PLoS One 2013;8(7):e68498 19 Citations |
1 | AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion. (Hong SK, Jeong JH, Chan AM, Park JI) Exp Cell Res 2013 Jul 15;319(12):1732-1743 19 Citations |
1 | P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. (Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, Tsimberidou AM, Kurzrock R) Oncotarget 2013 May;4(5):705-14 96 Citations |
1 | Polyunsaturated fatty acids affect the localization and signaling of PIP3/AKT in prostate cancer cells. (Gu Z, Wu J, Wang S, Suburu J, Chen H, Thomas MJ, Shi L, Edwards IJ, Berquin IM, Chen YQ) Carcinogenesis 2013 Sep;34(9):1968-75 53 Citations |
1 | Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. (Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F) Clin Cancer Res 2012 Oct 15;18(20):5816-28 128 Citations |
1 | Effect of the IGF-1/PTEN/Akt/FoxO signaling pathway on the development and healing of water immersion and restraint stress-induced gastric ulcers in rats. (Huang P, Zhou Z, Wang H, Wei Q, Zhang L, Zhou X, Hutz RJ, Shi F) Int J Mol Med 2012 Sep;30(3):650-8 21 Citations |
1 | PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. (Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J) Clin Cancer Res 2012 Mar 15;18(6):1777-89 186 Citations |
2 | Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. (Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H, Srinivasan R, Trimboli AJ, Martin CK, Li F, Yu L, Fernandez SA, Pécot T, Rosol TJ, Cory S, Hallett M, Park M, Piper MG, Marsh CB, Yee LD, Jimenez RE, Nuovo G, Lawler SE, Chiocca EA, Leone G, Ostrowski MC) Nat Cell Biol 2011 Dec 18;14(2):159-67 243 Citations |
1 | Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. (Wang S, Wu J, Suburu J, Gu Z, Cai J, Axanova LS, Cramer SD, Thomas MJ, Perry DL, Edwards IJ, Mucci LA, Sinnott JA, Loda MF, Sui G, Berquin IM, Chen YQ) Carcinogenesis 2012 Feb;33(2):404-12 43 Citations |
1 | Nitroglycerin drives endothelial nitric oxide synthase activation via the phosphatidylinositol 3-kinase/protein kinase B pathway. (Mao M, Sudhahar V, Ansenberger-Fricano K, Fernandes DC, Tanaka LY, Fukai T, Laurindo FR, Mason RP, Vasquez-Vivar J, Minshall RD, Stadler K, Bonini MG) Free Radic Biol Med 2012 Jan 15;52(2):427-35 22 Citations |
1 | Non-parametric population analysis of cellular phenotypes. (Singh S, Janoos F, Pécot T, Caserta E, Huang K, Rittscher J, Leone G, Machiraju R) Med Image Comput Comput Assist Interv 2011;14(Pt 2):343-51 9 Citations |
1 | A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. (Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R) Clin Cancer Res 2011 Nov 01;17(21):6840-6 45 Citations |
1 | Predictive and prognostic markers in colorectal cancer. (George B, Kopetz S) Curr Oncol Rep 2011 Jun;13(3):206-15 42 Citations |
1 | Pten in the breast tumor microenvironment: modeling tumor-stroma coevolution. (Wallace JA, Li F, Leone G, Ostrowski MC) Cancer Res 2011 Feb 15;71(4):1203-7 38 Citations |
2 | Allele-specific tumor spectrum in pten knockin mice. (Wang H, Karikomi M, Naidu S, Rajmohan R, Caserta E, Chen HZ, Rawahneh M, Moffitt J, Stephens JA, Fernandez SA, Weinstein M, Wang D, Sadee W, La Perle K, Stromberg P, Rosol TJ, Eng C, Ostrowski MC, Leone G) Proc Natl Acad Sci U S A 2010 Mar 16;107(11):5142-7 57 Citations |
2 | Pten in stromal fibroblasts suppresses mammary epithelial tumours. (Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N, Thompson JC, Caserta E, Wang H, Chong JL, Naidu S, Wei G, Sharma SM, Stephens JA, Fernandez SA, Gurcan MN, Weinstein MB, Barsky SH, Yee L, Rosol TJ, Stromberg PC, Robinson ML, Pepin F, Hallett M, Park M, Ostrowski MC, Leone G) Nature 2009 Oct 22;461(7267):1084-91 440 Citations |
1 | Cholesteatoma growth and proliferation: posttranscriptional regulation by microRNA-21. (Friedland DR, Eernisse R, Erbe C, Gupta N, Cioffi JA) Otol Neurotol 2009 Oct;30(7):998-1005 49 Citations |
1 | Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. (Miller TW, Pérez-Torres M, Narasanna A, Guix M, Stål O, Pérez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, Lindsley CW, Arteaga CL) Cancer Res 2009 May 15;69(10):4192-201 149 Citations |
1 | Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. (Berquin IM, Min Y, Wu R, Wu J, Perry D, Cline JM, Thomas MJ, Thornburg T, Kulik G, Smith A, Edwards IJ, D'Agostino R, Zhang H, Wu H, Kang JX, Chen YQ) J Clin Invest 2007 Jul;117(7):1866-75 217 Citations |
1 | Long-term pharmacological activation of PPARgamma does not prevent left ventricular remodeling in dogs with advanced heart failure. (Suzuki G, Khanal S, Rastogi S, Morita H, Mishima T, Anagnostopoulos PV, Nass O, Sharov VG, Tanhehco EJ, Goldstein S, Sabbah HN) Cardiovasc Drugs Ther 2007 Feb;21(1):29-36 7 Citations |
1 | Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. (Weng LP, Gimm O, Kum JB, Smith WM, Zhou XP, Wynford-Thomas D, Leone G, Eng C) Hum Mol Genet 2001 Feb 01;10(3):251-8 82 Citations |
1 | Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability. (Cohn DE, Basil JB, Venegoni AR, Mutch DG, Rader JS, Herzog TJ, Gersell DJ, Goodfellow PJ) Gynecol Oncol 2000 Oct;79(1):101-6 26 Citations |